ScreenerHero

FBRXForte Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · fortebiorx.com
76.92USD+0.03%Mkt Cap: 1.63B $P/E: —

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.63B $
Enterprise Value1.74B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-69.38M $
Revenue/Share—
Last Price76.92 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees23
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS34962G1094
Valuation
P/E (Trailing)—
P/E (Forward)-19.49
PEG—
EV/EBITDA-18.35
EV/Revenue—
P/S—
P/B32.64
EPS (TTM)-4.57
EPS (Forward)-3.94
52W Range
10.11100% of range77.19
52W High77.19 USD
52W Low10.11 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-113.75%
ROA-83.81%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-50.88M $
CapEx (TTM)116.00K $
FCF Margin—
FCF Yield-2.53%
Net Debt-198.46M $
Net Debt/EBITDA2.10
Balance Sheet
Debt/Equity—
Current Ratio10.01
Quick Ratio9.82
Book Value/Sh2.356 USD
Cash/Share7.880 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 16, 2020
Splits
Last Split1:25
Split DateAug 28, 2024
Analyst Consensus
Rating2.6 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)73.80 USD
Upside (mean)-4.1%
Target Range61.00 USD – 77.00 USD
$61.00-4.1% to mean$77.00
# Analysts5
Ownership
Shares Out.21.23M
Float18.67M
Insiders2.06%
Institutions96.59%
Short Interest
Short Ratio0.9d
Short % Float9.36%
Short % Out.9.30%
Shares Short1.90M
Short (prev mo.)1.89M
Technical
SMA 5047.98 (+60.3%)
SMA 20030.90 (+149.0%)
Beta2.65
S&P 52W Chg18.16%
Avg Vol (30d)2.17M
Avg Vol (10d)1.76M
Technical Indicators
RSI (14)85.1
MACD8.3197
MACD Signal10.0219
MACD Hist.-1.7021
BB Upper86.92 USD
BB Middle74.80 USD
BB Lower62.68 USD
BB Width32.41%
ATR (14)1.771 USD
Vol Ratio (20d)0.80x